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Although the MYC oncogene has been implicated in
cancer, a systematic assessment of alterations of
MYC, related transcription factors, and co-regulatory
proteins, forming the proximal MYC network (PMN),
across human cancers is lacking. Using computa-
tional approaches, we define genomic and proteo-
mic features associated with MYC and the PMN
across the 33 cancers of The Cancer Genome Atlas.
Pan-cancer, 28% of all samples had at least one of
the MYC paralogs amplified. In contrast, the MYC
antagonists MGA and MNT were the most frequently
mutated or deleted members, proposing a role
as tumor suppressors. MYC alterations were mutu-
ally exclusive with PIK3CA, PTEN, APC, or BRAF
alterations, suggesting that MYC is a distinct onco-
genic driver. Expression analysis revealed MYC-
associated pathways in tumor subtypes, such as
immune response and growth factor signaling; chro-
matin, translation, and DNA replication/repair were
conserved pan-cancer. This analysis reveals insights
into MYC biology and is a reference for biomarkers
and therapeutics for cancers with alterations of
MYC or the PMN.
INTRODUCTION
TheMYC gene was initially discovered as an oncogene (v-MYC)
acquired from the host cell genome by a subgroup of avian leu-282 Cell Systems 6, 282–300, March 28, 2018 ª 2018 The Authors. P
This is an open access article under the CC BY license (http://creativekemia viruses. Subsequently, the cellular MYC gene and its
paralogs (MYCN andMYCL) were found to be subject to genetic
alterations, such as amplification, chromosomal translocation,
and viral integration, in a broad spectrum of cancers leading to
tumorigenesis. In normal cells, expression of the endogenous
MYC gene is upregulated in response to diverse mitogenic and
developmental signals. The MYC protein functions as a tran-
scription factor that responds to and integrates these signals
into broad changes in gene expression, supporting cell growth
and proliferation.
Many of the genetic alterations that occur in tumors act to un-
couple MYC expression from its normal regulatory constraints,
thereby resulting in high levels of MYC protein that are less sen-
sitive to normal cellular and extracellular signals (for reviews see
Dang and Eisenman, 2014). Such alterations include (1) point
mutations in the MYC coding region that appear to increase
MYC protein stability and activity as secondary events to trans-
locations in lymphoma (Bahram et al., 2000; Hemann et al.,
2005); (2) mutation or rare amplification of distal enhancers
(Sur et al., 2012; Zhang et al., 2016); and (3) activating mutations
in signal transduction pathways (e.g., Wnt, Notch) that augment
MYC expression (Herranz et al., 2014;Muncan et al., 2006;Weng
et al., 2006). Even relatively small constitutive changes in MYC
expression level (>2-fold relative to normal) have been demon-
strated to have biological consequences and influence tumori-
genesis (Bazarov et al., 2001; Hofmann et al., 2015; Murphy
et al., 2008). Earlier studies showed that multiple cancer types
exhibit alterations at MYC family gene loci, usually associated
with increased MYC mRNA and/or protein levels (Nesbit et al.,
1999; Vita andHenriksson, 2006). Experiments in a number of tu-
mor lines and in animal models of cancer indicated that, in many
cases, MYC expression is required for tumor initiation, progres-
sion, or maintenance (for review see Gabay et al., 2014; Vita andublished by Elsevier Inc.
commons.org/licenses/by/4.0/).
Henriksson, 2006). Therefore, it is reasonable to consider tumors
with dysregulated MYC as ‘‘MYC-driven’’ or ‘‘MYC-addicted’’
tumors. However, the earlier meta-analyses indicated that within
a given tumor type or subtype the fraction of tumors with MYC
family gene rearrangements (amplification or translocations)
can vary widely. For example, based on different published
reports, MYC amplifications in breast cancer were found in
9%–48% of cases and 7%–78% in osteosarcoma (see Vita
and Henriksson, 2006). These and other variations are likely
due to different methodologies employed to detect rearrange-
ments and to differences in sample sizes. More recently, a report
broadly analyzing the landscape of focal amplifications in can-
cers found MYC amplification to be among the most frequent
of all such events (Beroukhim et al., 2010).
The functional consequences of MYC de-regulated expres-
sion and its influence on gene expression programs and DNA
replication or repair processes during normal and oncogenic
proliferation have been a subject of intense research (Domi-
nguez-Sola and Gautier, 2014; Sabo and Amati, 2014; Walz
et al., 2014). MYC functions with its heterodimerization partner
MAX, through recognition of specific DNA elements (Blackwell
et al., 1993; Fernandez et al., 2003; Grandori et al., 1996; Guc-
cione et al., 2006), and recruitment of transcriptional co-regula-
tory molecules linked to histone acetylation (Bouchard et al.,
2001; Frank et al., 2001) to elevate expression of a broad, but se-
lective, set of genes via the activation of specific chromatin
marks. Upon dysregulation and overexpression, MYC binds to
lower-affinity sites in promoters and enhancers in a dose-depen-
dent manner resulting in ectopic regulation (activation or repres-
sion) of thousands of genes (between 2,000 and 4,000 genes
[de Pretis et al., 2017; Sabo` et al., 2014]). In addition, a role for
MYC in the global mRNA amplification observed during transi-
tion from quiescence to proliferation was proposed by exam-
ining gene expression changes in a B cell line, whose prolifera-
tive state was strictly dependent on a conditional MYC allele
(Lin et al., 2012; Nie et al., 2012). Recent evidence, however, in-
dicates that this may be largely an indirect effect of MYC as the
amplification of the majority of mRNAs does not correlate with
binding of MYC at their promoters (Kress et al., 2015).
While the effects of MYC as a transcription factor are often
considered in isolation, it is important to consider its function
in the context of a network of related transcription factors and in-
teracting co-regulatory proteins that have the potential to influ-
ence MYC target gene binding and expression. We refer to this
network as the proximal MYC network (PMN), which includes
MAX, MGA, MXD1, MXD3, MXD4, MXI1, MNT, MLX, MLXIP,
and MLXIPL. All of these proteins have related basic-helix-
loop-helix zipper (bHLHZ) domains and can be considered
members of the MYC bHLHZ superfamily. The different compo-
nents of the network are connected through dimerization with
MAX, MLX, or both. MAX, in addition to dimerizing with MYC pa-
ralogs, also forms heterodimers with the MXD family, comprised
of MXI1, MNT, and MGA (Ayer et al., 1993; Hurlin et al., 1995,
1997, 1999; Meroni et al., 1997; Zervos et al., 1993) (Figure 1A).
Although far less characterized thanMYC proteins, these factors
can compete with MYC for binding to MAX and for E-box sites in
shared target genes. In contrast to the predominant transcrip-
tional activation function of MYC, the MXD, MXI1, MNT, and
MGA proteins repress transcription through the recruitment ofcorepressor complexes (for reviews see Conacci-Sorrell et al.,
2014; Link and Hurlin, 2015). These opposing transcriptional ac-
tivities, together with functional assays showing that MXDs,
MNT, andMGAproteins can antagonize the transforming activity
of MYC in cell culture assays, raised the possibility that they
function as tumor suppressors. Supporting this hypothesis,
recurrent deletions in MXDs, MNT, and MGA genes have been
identified in some human tumors (Edelmann et al., 2017), and
mouse studies suggest that at least MNT and MXI1 can behave
as tumor suppressors (Dezfouli et al., 2006). By contrast, loss of
MNT, such as dysregulated MYC, is pro-apoptotic, can exacer-
bate the apoptotic activity of MYC, and abrogate MYC-driven
tumorigenesis (Link et al., 2012). A model that emerges from
these studies is that a balance between the abundance and ac-
tivity of MYC and MNT, and perhaps more generally between
MYC, MXDs, MNT, and MGA, is needed to support oncogenesis
(Diolaiti et al., 2015; Link and Hurlin, 2015). Moreover, the
MAX-like protein MLX forms dimers with MLXIP and MLXIPL
transcription factors (also known as MONDOA and CHREBP,
respectively), which can either support or antagonize MYC func-
tion depending on cell context (Wilde and Ayer, 2015). Impor-
tantly, the nuclear localization and transcriptional activity of
MLXIP and MLXIPL is highly dependent on nutrient flux, poten-
tially connecting the functions of MYC and other PMN members
to cellular metabolic state (Carroll et al., 2015; Diolaiti et al., 2015;
Wilde and Ayer, 2015). Finally, different PMN members recruit
other transcription factors, chromatin modifiers, and ubiquitin li-
gases that control their activity and abundance. Thus, changes in
the copy-number, mutation, expression, and other alterations of
PMN members and their interacting proteins may influence
oncogenesis by increasing MYC expression, co-operating with
or antagonizing MYC activity, and directly altering gene expres-
sion patterns independent of MYC, or a combination of these
mechanisms (Diolaiti et al., 2015; Yang and Hurlin, 2017).
Here we performed a broad and unified analysis of genomic
and expression data of the The Cancer Genome Atlas (TCGA)
dataset with <9,000 samples covering 33 tumor types. We
analyzed the frequency and extent of copy-number changes
and mutations of MYC paralogs at the pan-cancer level. This
was integrated with existing knowledge about MYC and the
PMN to better understand the different roles that alterations of
MYC and the PMN play on a pan-cancer level and in individual
tumor types.
RESULTS
Pan-cancer Analysis of Copy-Number Alterations
MYC oncoproteins in solid tumors are mainly activated by copy
gains, and it is well established that even small changes in MYC
levels can drive ectopic proliferation of somatic cells and onco-
genesis (Bazarov et al., 2001; Hofmann et al., 2015; Murphy
et al., 2008). Therefore, we performed an in-depth analysis of
copy-number alterations using purity- and ploidy-corrected
focal copy-number data to provide the sensitivity necessary to
detect low level copy-number gains expected to have a biolog-
ical function. Focal copy-number events are defined by affecting
less than 50%of the chromosome arms. At the pan-cancer level,
MYC (c-MYC) is the most frequently amplified gene among the
proximal network members across all cancer types, occurringCell Systems 6, 282–300, March 28, 2018 283
Figure 1. Proximal MYC Network
(A) Percentage of samples across 33 tumor types with focal range copy-number amplifications (leftmost box, red), focal range deletions (middle box, blue), and
coding mutations (rightmost box, green) per gene of the MYC network.
(B–D) Oncoprint for focal amplifications of MYC, MYCN, and MYCL (B). Focal amplifications (C, red) and focal deletions (D, blue) across genes in the proximal
MYC network visualized by the distribution of alteration size and amplitude. Oncogenes and tumor suppressors outside of the MYC network (denoted by *) were
included for reference.
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in 21% of samples (Figure 1A). MYCN and MYCL exhibit 7%
focal amplification at a pan-cancer level. Overall, 28% of the
analyzed samples in TCGA have at least one of the three MYC
family members focally amplified (Figure 1B). The most frequent
focal deletions in the PMN, including shallow deletions (only one
copy of the gene lost), were seen in the transcriptional repressor
and MYC antagonist,MNT (10%), aligning with its proposed role
as a tumor suppressor in the MYC network (Yang and Hurlin,
2017) (Figure 1A). Deletions of the closely related MXD3 (7%),
and MXD4 (6%) genes, as well as of MGA (8%), were also
observed at the pan-cancer level. Shallow deletions of MAX
were found in 5% of all TCGA samples. Even though the associ-
ation of MAX with MYC is critical for its transforming potential in
cell culture assays, recurrent shallow deletions of MAX were
observed in some cancers, particularly pheochromocytomas
and gastrointestinal stromal tumors (Burnichon et al., 2012;
Comino-Me´ndez et al., 2011; Pantaleo et al., 2017; Schaefer
et al., 2017). These findings raise the possibility that the loss of
MAX dimerization with MXD, MNT, and MGA, all transcriptional
MYC antagonists, favors tumorigenesis for some cell types.
Also, forMLX, shallow deletions were observed in 5% of tumors
(Figure 1A). MLX is an obligatory dimerization partner with the
MONDO family (MLXIP orMLXIPL), but can bindMNT and a sub-
set of MXD proteins (Figure 1A). Similar to MAX, shallow deletion
of MLX could interfere with the repressor activity of MXD and
MNT, as well as alter MYC-induced metabolic reprogramming
by disabling of MLXIP and MLXIPL (O’Shea and Ayer, 2013).
The same analysis was performed considering broad
deletions and amplifications using a cutoff of ±0.5 ploidy for
the relative copy-number values (pan-cancer distribution shown
in Figure S1B). This cutoff enabled the detection of copy-number
gain or loss of a single MYC allele present in 100% of cells in the
sample. Unlike focal events, the broad copy-number alterations
can involve whole chromosome arms. In this case,MYC amplifi-
cation frequency increases to 30% and the frequency of MNT
deletions doubles (21%) (Figure S1C). The latter may be due to
MNT and TP53 being on the same distal arm of chromosome
17. For the rest of the PMN, both broad and focal copy-number
events occur at similar frequencies.
Distinct Subgroups Based on Chromosome Fraction and
Copy Number
To learn more about the characteristics of focal copy-number
alterations, we plotted the amplitude of copy gain or copy
loss against the fraction of the chromosome affected (Figures
1C and 1D). Only samples with focal GISTIC +1 and 1 were
considered. Even though focal deletions were defined as less
than 50% of the chromosome arm, this graphical representa-
tion highlights that the majority of events affect about 20% of
the chromosome arm. Furthermore, distinct groups emerge
based on amplitude and size. MYC amplifications (Figure 1B),
for instance, shows three distinct groups: low copy increase
affecting everything from small amplicons up to large (40% of
the chromosome arm), an intermediate copy gain group with
mostly large events, and a small subset with high copy gains
affecting a small proportion of the chromosome. These pat-
terns are similar to clinically significant drivers such as EGFR,
CCND1, and ERBB2, with the only difference of MYC having
also larger amplifications. MYCN only shows one group withlow copy gain affecting a large proportion of the chromosome
arm (Figure 1B).
Deletions in the PMN are mostly shallow, only affecting
one copy of the gene, in contrast to known tumor suppressors
such as CDKN2A and PTEN (Figure 1D). MNT, the most
frequently deleted member of the PMN, shows a wide distribu-
tion in the size of the deletions.
Pan-cancer Frequency of Mutations in PMN
Mutations in MYC that may affect MYC protein stability and/or
activity have been described to occur in Burkitt’s lymphoma
and diffuse large B cell lymphoma (Adhikary et al., 2005; Sal-
ghetti et al., 1999; Zhang et al., 2013). In this analysis, recurrent
mutations altering two particular amino acids (P74 and S161)
were observed at a frequency of 0.07% (Figures 1A and
S1D). P74 is within the MYC box 1 phosphodegron (sequence
conserved for all FBXW7 degrons) and is strongly predicted to
inactivate the degron and lead to increased stability of MYC
(O’Neil et al., 2007). S161 is proximal to the 30 end of MYC box
II, and sinceMYCbox II is themajor binding site for MYC co-acti-
vator complexes, it is possible that phosphorylation of S161may
influence transcriptional activity. The serine in this position is not
conserved, while the core of MYC box II is highly conserved in
MYC paralogs.
In addition, MGA was mutated at 4% across all cancer types,
with 30% of the 523 mutations identified in MGA predicted to
truncate the protein, thereby eliminating the bHLHZ domain
and interaction with MAX (Washkowitz et al., 2015) (Figure S1E).
Such loss of function mutations in MGA, an essential gene en-
coding a >3,000 amino acid protein that contains both T-box
and bHLHZ DNA binding domains, were recently reported to
occur in chronic lymphocytic leukemia (De Paoli et al., 2013)
and lung adenocarcinomas (Cancer Genome Atlas Research
Network, 2014a).
Genetic Alterations among Individual Cancer Types
In addition to comprehensive characterization of MYC and PMN
alterations across all TCGA samples, genetic alterations in indi-
vidual cancer types were evaluated (for cancer-type-specific
abbreviations, see Table S1). The data are presented as hierar-
chically clustered heatmaps highlighting tumor types with similar
patterns. Focal amplifications involving MYC (Figure 2A) occur
most frequently in OV (64.8%), followed by ESCA (45.3%) and
LUSC (37.2%). These tumor types group together with UCS
and BLCA for a clear subgroup highlighted by frequent amplifi-
cations of all MYC paralogs. A second group with high MYC
amplification, but lower percentages for MYCN and MYCL, in-
cludes STAD, LUAD, BRCA, and LIHC. The exception among
the 33 cancer types are THYM, THCA, KICH, LAML, KIRP, and
PCPG, which have infrequent amplifications of MYC paralogs
and the PMN (between 5 and 0.4%). The same group of tumor
types has also very few deletions among members of the
PMN. In general, 23/33 cancer types have at least 10% of sam-
ples with MYC focally amplified, whereas MYCL and MYCN are
amplified less frequently thanMYC. Data for broad amplification
are shown in Figure S3A, indicating that in UVM and KIRP the
majority of amplifications are not focal.
Among the PMN, MNT was the most focally deleted gene
occurring in more than 20% of LIHC, LUAD, SARC, and UCSCell Systems 6, 282–300, March 28, 2018 285
samples. However, other PMN members involved in E-box tran-
scription repression, such asMGA andMXI1, are also frequently
deleted.
Because multiple members of the PMN act co-operatively or
antagonistically, and show cross-regulation, the network can
be considered as a single transcriptional module, we combined
focal deletions in suppressors (e.g.,MNT,MGA), focal amplifica-
tion in drivers (e.g., MYC) and mutations (e.g., MGA) of all PMN
members. Based on this analysis, almost every cancer type
has at least one member of the PMN affected in at least 10%
of the samples (Figure 2D), and 24/33 tumor types exhibit alter-
ation in at least 50% of the samples. The percentage of alter-
ations varies widely among tumor types, with OV cancer
showing almost 100% samples with alterations in the MYC
network, whereas THCA exhibits less than 5% of samples with
MYC/PMN alterations (Figure 2D).
Tumor-Type-Specific Amplification Size of MYC
The size of amplifications involving MYC varies among tumor
types. We defined an arbitrary threshold of 0.1 to separate
the amplifications into two groups based on the chromosome
fraction affected. On a pan-cancer level, 75% of samples
with MYC focal amplification have events affecting more than
a 0.1 fraction of the chromosome arm, and for 25% the fraction
of the chromosome is less than 0.1, similar to the range
observed for other drivers such as EGFR and ERBB2 (Figures
1B and 2E). Individual tumor types, such as UCEC, STAD,
ESCA, UCS, and SARC, have significantly more amplification
events, which affect less than a 0.1 fraction of the chromosome
arm. For LUSC, HNSC, LIHC, LGG, UVM, and SKCM on the
other side, larger amplicons are more frequent (Figures 2F
and S3C). Among tumor subtypes, a significant difference
was detected only in ESCA (Figure S3D), where small amplifi-
cation of MYC are more frequent in the chromosomal instability
subtype.
Pan-cancer Analysis Reveals Mutual-Exclusivity
between MYC Alterations and Common Oncogenic
Drivers
The large number of samples in the TCGA (9,125 samples), and
the fact thatMYC is frequently altered across many tumor types,
prompted us to look for genes with alterations that are either
mutually exclusive or co-occurring withMYC. However, the anal-
ysis for co-occurrence with all genetic alterations (copy number
and mutations) typically returned genes located within the same
chromosome arm asMYC (Figure S3A). We therefore focused on
mutual exclusivity allowing for the discovery of alterations (copy
number and mutation), which occur more frequently than ex-
pected by chance without MYC. We used the DISCOVER
method (Canisius et al., 2016) to calculate the significance that
alterations in a given gene are less likely to co-occur with
MYC. With a false discovery rate of 1%, 370 genes were found
to be mutually exclusive with MYC. Most strikingly, the top four
most significant genes were all known oncogenic drivers:
PTEN, BRAF, APC, and PIK3CA (Figures 3A and 3B; Table S2).
Additional known oncogenes identified had higher but still
significant q values, such as KRAS, NRAS, IDH1, and MTOR.
On a pan-cancer level we did not observe any mutual exclusivity
between MYC and other members of the PMN.286 Cell Systems 6, 282–300, March 28, 2018Oncogenic drivers could simply be inducing MYC expression
and might therefore appear to be mutually exclusive. We there-
fore compared MYC expression between gene of interest
altered, MYC altered, both altered, or none of them (Figure 3C).
In the case of PTEN and BRAF,MYC expression levels were un-
changed in the presence of alterations in these genes, suggest-
ing that MYC was not induced in these tumors. In the case of
APC and PIK3CA alterations, MYC expression was elevated
suggesting that these alterations are sufficient to activate MYC
expression, without the need of gene amplification, consistent
with previous reports (Ilic et al., 2011; Muncan et al., 2006).
The same analysis was performed for individual tumor types
(Table S2; Figures 4A–4C). Only 3 out of the 33 tumor types
had significant results: BRCA (33.4% MYC alterations), UCEC
(21.5% MYC alterations), and LGG (12.3% MYC alterations). In
BRCA, PIK3CA alterations are mutually exclusive with MYC
alterations (Figure 4A; Table S10). UCEC had ten significantly
mutually exclusive genes, of which eight are shown. The list in-
cludes PTEN and KRAS as common oncogenic drivers (Fig-
ure 4B; Table S10). In LGG cancers, mutations of the CIC and
FUBP1 genes were mutually exclusive with MYC. FUBP1 is
known to bind to regulatory sequences of MYC and in the
absence of this transcription factor, endogenous expression of
MYC is blocked (He et al., 2000), indicating the functional depen-
dence of MYC from FUBP1.
ElevatedMYC Expression acrossMultiple Cancer Types
As described in the Introduction, genetic alterations alone are
not sufficient to characterize all MYC-driven tumors, and we
therefore proceeded to analyze MYC expression levels across
the 33 cancer types. Overall, MYC expression was significantly
(Hedges’ g effect size = 0.71) increased in the samples with so-
matic MYC alterations, but not in samples where alteration only
occurred in a PMN member (Hedges’ g effect size = 0.17; Fig-
ure 5A). Similar observations were made for MYCN and MYCL
(Figures 5B and 5C). The lack of effect of PMN alterations on
MYC expression is consistent with reports that PMN members,
such asMNT andMGA (Hurlin et al., 1997, 1999) are antagonistic
of MYC transcriptional targets but not of the MYC gene itself.
MYC levels can also be altered through upstream signal trans-
duction pathways, epigenetic changes, and regulation of mRNA
and protein stability.MYCmRNA levels were elevated inmost tu-
mor types, with highest levels detected in COAD, HNSC, ESCA,
READ, and UVM, followed by OV, LUSC, MESO, SKCM, and
STAD (Figure 5D). Interestingly, cancers with infrequent amplifi-
cation of MYC also had the lowest expression levels: KICH,
PCPG, and THCA. In summary, cancers with the highest fre-
quency of MYC copy-number gains showed elevated average
expression at the mRNA level.
In addition, because MYC has been well established to be
post-transcriptionally regulated by multiple ubiquitin/proteaso-
mal degradation pathways, we analyzed protein expression
data which were quantified using the reverse phase protein array
(RPPA) platform. These data are available for MYC, but not for
MYCN or MYCL. MYC protein levels are the highest in OV and
KICH, which is in concordance with the high frequency of copy-
number increases of MYC in OV cancer (Figure 5E). MYC-low
mRNA expression and infrequent gene amplification in KICH
suggests that MYC is stabilized either by a post-translational
Figure 2. Tumor-Type-Specific Alterations of PMN Members
(A) Percentage of samples with focal amplifications per gene per tumor type.
(B) Percentage of samples with focal deletions respectively per gene per tumor type.
(legend continued on next page)
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mechanism, or translation itself could be regulated in this cancer.
Colorectal cancer was the third highest cancer with MYC protein
level, possibly explained by the activation of the Wnt/b-catenin
signaling pathway occurring in the majority of colorectal cancer
samples (Ciriello et al., 2013). Brain tumors, LGG, and GBM,
had the lowest levels of MYC protein. It has been shown in pedi-
atric GBM that MYCN is mostly elevated (Huang and Weiss,
2013), but our data show elevated mRNA levels for both MYCN
and MYC. LGG, on the other hand, have higher MYCN mRNA
levels compared with MYC. Lower MYC protein was also de-
tected using RPPA data in DLBC, with only a small subset
(5%–10%) exhibiting high MYC protein expression. Generally,
MYCmRNAcorrelateswell withMYCprotein levels inmost tumor
types, with UVM, CHOL, ACC, and KICH being notable excep-
tions (Figure 5F).
In contrast to MYC, MYCN mRNA expression was overall
lower at the pan-cancer level, with the most prominent increase
detected in a small subset of cancer types, namely: LGG, OV,
PCPG, TGCT, and GBM. This highlights a more disease/tissue-
specific expression pattern forMYCN compared withMYC (Fig-
ure 5D). However, MYCN gene amplification status across a
variety of cancer types (Figure 1B) was not limited to these tis-
sues, indicating that MYCN alterations are widespread across
different tissues.
Unique Gene Set Enrichment Patterns for MYC
To find gene sets which are associated with activation of the
MYC pathway, MYC and MYCN expression were utilized to
identify sets of genes with both significant positive and nega-
tive Spearman rank correlation coefficients in a pan-cancer level.
The coefficients were then used to generate aweighted genome-
wide gene list to be used for gene set enrichment analysis. For
this analysis, gene ontology molecular function category
comprising 901 gene sets was corrected for redundancy and
reduced to 396 gene sets (using the reduce_overlap function
of the R GOplot package, see Tables S4 and S5). From the posi-
tively correlated gene sets a commonly shared pan-cancer en-
riched gene set emerged, with the exception of THCA, PCPG,
and TGCT. Heatmaps derived from the enrichment scores of
the top 100 pathways are shown for MYC and MYCN (Figures
6A and 6B; Table S6). Hierarchical clustering of cancer types
and positively correlated pathways defines three groups, mainly
distinguished by both the strength of correlation with MYC
expression as well as the specific enrichment of certain gene
sets (designated groups I, II, and III in Figure 6A). Groups I
and II, together comprising 30 cancer types, showed the highest
similarity, with enrichment of pathways that is in line with previ-
ous knowledge and are therefore referred as ‘‘canonical’’ MYC
gene sets, such as transcription and RNA processing, chromatin(C) Percentage of samples with protein coding mutations per gene per tumor typ
(D) Percentage of samples showing any alterations in at least one of the PMN m
(E) Focal amplification ofMYC visualized by the distribution of alteration size and a
amplification larger than a 0.1 fraction of the chromosome arm, or less than 0.1.
(F) Diagram of various metrics calculated for focal copy-number amplifications ta
given tumor type with focal amplifications that span greater than a 0.1 fraction of
Fisher’s exact tests comparing the fractions of samples on either side of the 0.1
representing the equivalent of p = 0.05. TheGISTIC peak q value (right) is only avail
number amplification affectingMYC, with the red line representing the equivalent
one asterisk (*), whereas tumor types which have significantly larger amplificatio
288 Cell Systems 6, 282–300, March 28, 2018remodeling (L€uscher and Vervoorts, 2012; Nakagawara et al.,
1987), and translational processes (Cowling and Cole, 2007),
including gene sets corresponding to ribosomal structural com-
ponents and rRNA synthetic apparatus (Grandori et al., 2005;
Grewal et al., 2005), as well as DNA replication and repair (Dom-
inguez-Sola and Gautier, 2014; Rohban and Campaner, 2015).
The canonical signature was the predominant feature of the 14
tumor types of group I, exhibiting MYC amplification in >20%
of samples, indicating that these expression changes are linked
to de-regulated MYC expression from gene copy-number alter-
ations (Figure 6A).
Interestingly, this broad and unbiased pan-cancer analysis
also revealed a new aspect of MYC-associated broad transcrip-
tional changes in groups II and III. These groups are character-
ized by gene sets enriched for cytokines, immune response,
and extracellular matrix components. In addition, groups II and
III shared enrichment for growth factor signaling pathways,
consistent with the notion that MYC can be induced in response
to several extracellular stimuli, thus linking activation of the MYC
pathway to microenvironment cues in a subset of cancers. For
simplicity, we will refer to the chemokine/immune-response
and signaling signature to as ’’non-canonical’’ MYC signatures
(see Figure 6A, highlighted in orange). Among the signaling/
growth factor pathways were transforming growth factor b,
epidermal growth factor receptor (EGFR), insulin receptors, hor-
mone receptors, and G-protein-coupled receptors, indicating
that a diversity of signaling pathways may be able to activate
MYC or vice versa, and that MYC could affect their expression.
WNT signaling was found to be enriched across all three groups,
with the highest enrichment score in cancers of group III. The
notion that elevated MYC expression in certain cancers occurs
irrespective of gene amplification events is exemplified by the
activity of WNT in COAD and READ. These cancer types exhibit
the highest levels ofMYCmRNA expression, yet not the highest
percentage ofMYC gene amplification; also KIRP and KIRC both
exhibit elevatedMYCmRNA expression (see Figure 5D), despite
low percentage of MYC amplification (2%–3%). Altogether,
these results underline the importance of signaling pathways
contributing toMYC elevated expression in many cancers. Strik-
ingly, group III, which consists of only three cancer types, TCGT,
THCA, and PCPG, exclusively exhibited high correlation with the
‘‘non-canonical MYC signature,’’ comprising cytokine, immune
response, and signaling pathways, but lacking hallmarks of the
canonical MYC signature. Interestingly, these three cancers
exhibit low MYC expression (Figure 5D) and low percentage of
MYC copy-number alterations (see Figure 2B).
Overall, the definition of MYC-associated gene expression
at the pan-cancer level confirmed known hallmarks of MYC
pathway activity across 30 of the 33 cancer types, while alsoe.
embers per tumor type.
mplitude. An arbitrary threshold of 0.1 was used to define two groups with either
rgetingMYC. Proportion > 0.1 (left) demonstrates the amount of samples for a
the chromosome arm. Fisher’s exact test p value metric (middle) resulted from
cutoff for each tumor type with the rest of the tumor types, with the red line
able for tumor types in whichGISTIC identified significant regions of focal copy-
of q = 1.00. Tumor types with significantly smaller amplification are labeled with
ns are labeled with two asterisks (**).
(legend on next page)
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revealing novel associations for example with immune response
and cytokine signaling for future studies.
Unique Gene Set Enrichment Patterns for MYCN
While MYCN was less prominently amplified at the pan-cancer
level than MYC (7% versus 21%), several cancer types such
as UCS, TGCT, OV, LUSC, ESCA, and BLCA had elevated
copy-number changes (>10%), which was also reflected in
higher MYCN expression levels. To explore potential differ-
ences and/or similarities with respect to global gene expres-
sion signatures between these two MYC paralogs, a
genome-wide correlation with MYCN across the 33 tumor
types was also carried out. This analysis revealed common
features with MYC-associated pathways as well as MYCN-
specific gene sets (Figure 6B). Among the MYCN-associated
signature, across all cancers with the exception of LAML,
LGG, and TGCT, was the enrichment for cell-signaling and
developmental pathways including WNT, NOTCH, and Ephrin
receptors. Interestingly, gene sets enriched for WNT signaling
appeared more significantly in MYCN than MYC, and alto-
gether developmental pathways were highly represented in
the MYCN-associated gene expression signature. Similar to
MYC, the MYCN pan-cancer signature was enriched for
epigenetic pathways linked to histone acetylation and chro-
matin modifications. Metabolism linked genes were noted as
MYCN-associated across all cancer types, but only detected
on a cancer-type basis for MYC.
Unsupervised clustering of the positively correlated gene set
distinguished three major groups (Figure 6B). Groups II and III
were most similar with respect to cell-signaling, and also char-
acterized by enrichment for neuronal function gene sets,
including genes related to glutamate receptor function,
ligand-gated ion channels, calcium ion transport, and acetyl-
choline binding. This neuronal-like signature (Figure 6B, light
orange) is another distinguishing feature between MYCN and
MYC paralogs. Group III and, to a lesser extent group II,
also contained the ‘‘non-canonical’’ MYC signature, including
cytokine, immune system, and extracellular matrix genes.
However, the cancer types exhibiting the non-canonical signa-
ture did not overlap with MYC cancer types with such a signa-
ture, except for all the kidney cancers: KIRP, KIRC, and KICH
(Figure 6B).
Finally, group 1, comprising LAML, LGG, TGCT, READ,
PAAD, BLCA, THCA, PCPG and GBM, OV and COAD, corre-
lated with MYC canonical signature with respect to DNA repli-
cation/repair and chromatin. Interestingly this group contained
cancer types with the highest MYCN expression (see Fig-
ure 5D) such LGG, GBM and TGCT, and OV. This observation
is consistent with the high threshold level of MYCN reached in
these cancers, to potentially drive the canonical signature. InFigure 3. Pan-cancer Mutual Exclusivity with Focal Copy-Number Eve
(A) Oncoprint of MYC with the four most mutually exclusively altered genes PTEN
(B) The table lists the top four genes most mutually exclusive with respect toMYC
with just the gene altered, with justMYC altered, and with bothMYC and the gene
method.
(C) Boxplots compareMYC expression between groups of samples defined by p
MYC. Hedges’ g effect sizes are indicated for each pair of boxplots. NS indicate
tude <0.5 (small) and ** indicates an effect size magnitude <0.8 (medium).
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kine/immune system as well as gene sets related to cell
signaling (Figure 6B). In summary, while both MYC- and
MYCN-enriched pathways commonly exhibited hallmarks of
the canonical MYC signature, MYCN was unique in its associ-
ation with genes related to neuronal function and develop-
mental pathways.
APan-cancerMicroRNA Signature AssociatedwithMYC
MicroRNAs (miRNAs) are key regulators of gene expression and
important players in the pathogenesis of human cancers (Bartel,
2004; Ventura and Jacks, 2009). To gain insights into the interac-
tion betweenmiRNAs andMYC in human cancers, we calculated
the Spearman rank correlation coefficients between 662 human
miRNAs and MYC mRNA levels across each of the 33 cancer
types. This analysis revealed a subset of miRNAs whose expres-
sion correlates with MYC levels across multiple cancer types.
Eighty-two miRNAs showed an absolute Spearman rho correla-
tion greater than 0.35 in at least three of the 33 cancer types
examined. Based on their correlation to MYC levels, these
miRNAs can be divided in three major groups (Figure 7).
The first include miRNAs whose expression positively cor-
relates with MYC expression across the vast majority of
studies. This group is largely composed by members of the
miR-17–92 cluster and of its paralog, miR-107b–25. miR-
17–92 is a polycistronic miRNA locus encoding six distinct
miRNAs (miR-17, miR-18a, miR-19a, miR-19b-1, miR-20a,
and miR-92a-1). Studies in mouse models of human cancers
have demonstrated that this cluster, also known as Oncomir-
1, is a bona fide oncogene and a direct MYC transcriptional
target (He et al., 2005; O’Donnell et al., 2005). Furthermore,
induction of miR-17–92 by MYC has been reported to
be crucial for tumor cell survival and for tumor progression
in multiple cancer types (Han et al., 2015; Li et al., 2014;
Mu et al., 2009; Olive et al., 2009). miR-21, another bona
fide human oncogene (Medina et al., 2010), and miR-27a,
also are also generally positively correlating with MYC
expression.
The second group consists of miRNAs, whose expression is
consistently negatively correlated with MYC. Prominent exam-
ples are members of the miR-29, miR-30, miR-125a, and let-7
families of miRNAs. These miRNAs have been previously shown
to be directly repressed by MYC (Chang et al., 2007), and are
suspected to act as potential tumor suppressors. Other promi-
nent miRNAs belonging to this second group are miR-200a
andmiR-200b. These two relatedmiRNAs have been extensively
studied and linked due their ability tomodulate epithelial-mesen-
chymal transition (EMT) by forming a negative feedback loop
with the master transcription factors ZEB1 and ZEB2 (Burk
et al., 2008; Gregory et al., 2008; Korpal et al., 2008; Parknts and Mutations of MYC
, BRAF, APC, and PIK3CA.
. Columns 2–5 show counts of samples with no alterations inMYC or the gene,
altered. Columns 6 and 7 show p and q values as computed by the DISCOVER
airwise alteration status of PTEN, BRAF, APC, and PIK3CA, respectively, with
s an effect size magnitude <0.2 (negligible), * indicates an effect size magni-
Figure 4. Cancer-Type-Specific Mutual Exclusivity with MYC
(A–C) Oncoprints for genes significantly mutually exclusive with MYC within BRCA, UCEC (top 8 genes are shown), and LGG, respectively.et al., 2008). Consistent with this model, downregulation of these
two miRNAs has been shown to be sufficient to promote EMT,
while their overexpression can prevent EMT and inhibit cancer
cell migration (Korpal et al., 2008).
Finally, a third and larger group of miRNAs was identified
whose expression correlates withMYC in only a more restricted
subset of cancer types, or that show positive correlation in some
studies, but negative correlation in others. Several notable puta-
tive oncogenic and tumor-suppressive miRNAs belong in this
group. For example, expression of miR-221 and miR-222, which
have been proposed to promote cell proliferation and tumorigen-
esis, at least in part via p27-Kip repression (Kedde et al., 2010;
Kim et al., 2009; Korpal et al., 2008; le Sage et al., 2007), posi-tively correlated with MYC levels in PCPG, BLCA, CESC, and
TGCT, but negatively correlated in THYM, LGG, and SKCM. A
similar behavior is observed for miR-150, miR-155, miR-223,
and miR146b.
Overall, these data show that there is clear correlation be-
tween MYC expression and several key oncogenic miRNA
expression across multiple human cancers.
DISCUSSION
MYC was discovered nearly four decades ago, and since that
time has been the subject of over 26,000 publications resulting
in a substantial amount of information about the normal andCell Systems 6, 282–300, March 28, 2018 291
Figure 5. MYC Expression
(A–C) Comparison ofMYC,MYCN, andMYCL expressions, respectively, between cohorts defined by focal amplification state of the genes themselves. For each
of the three genes, from left to right, the boxplots represent: a cohort with any PMN gene other thanMYC, MYCN, or MYCL altered, respectively, a cohort with
MYC, MYCN, or MYCL amplified, respectively, and a cohort with no PMN genes altered. NS indicates an effect size magnitude <0.2 (negligible), * indicates an
effect size magnitude <0.5 (small), ** indicates an effect size magnitude <0.8 (medium), and *** indicates an effect size magnitudeR0.8 (large).
(D) Distribution of MYC and MYCN gene expression per tumor type.
(F) Distribution of MYC protein expression per tumor type.
(E) Correlation between median MYC mRNA expression and median MYC protein expression per tumor type.
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Figure 6. Pan-cancer Gene Set Enrichment Patterns
(A and B) Heatmap shows clustering of tumor types based on top 100 most positively correlated gene sets from gene ontology molecular function category for
MYC (A) and MYCN (B). Each cell of the heatmap is colored by the normalized enrichment score of a gene set for a tumor type. Gray cells indicate lack of
(legend continued on next page)
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oncogenic functions of MYC. The involvement of MYC as an
oncogenic driver was described in a wide spectrum of tumor
types as shown by early reports in leukemia (Dalla-Favera
et al., 1983; Nowell et al., 1983), B cell lymphomas (Hayward
et al., 1981), lung cancer (Little et al., 1983), and neuroblastoma
(Schwab et al., 1983). Many of the analyses of MYC alterations in
different tumor types have been scattered among many publica-
tions and meta-analyses. The TCGA permits for the first time a
pan-cancer analysis of theMYC network using a uniform dataset
and brings the field a step closer to classify tumors with and
without MYC alterations. Gene amplifications of MYC paralogs
occur in 28% of all cancer samples analyzed herein, suggesting
that MYC paralogs have an important function in tumorigenesis
with potential therapeutic implications for many of the 33 major
cancer types described by TCGA.
Because MYC and its proximal network are altered in multi-
ple ways, characterization by MYC copy number alone is insuf-
ficient to reveal the extent of MYC involvement in tumorigenesis.
Therefore, the present analysis also includes genetic alterations,
mRNA, and protein expression analysis of MYC paralogs (MYC,
MYCN, and MYCL), and alterations of genes comprising the
PMN, a group of MYC-related transcription factors that have
been implicated in MYC pathway activity.
PMN Balance
MYC is the only member of the PMN which shows mainly ampli-
fications, while MAX, MNT, and MGA have predominantly
shallow deletions. All other members of the PMN display a
mixture of amplifications and deletions raising the possibility
that cells have to maintain a specific balance in the network.
The partial loss of MAX, an essential dimerization partner of
MYC, seems to be counterintuitive, but loss of MAX dimerization
with MXD, MNT, and MGA, all transcriptional MYC antagonists,
may play a critical role in tumorigenesis for some cell types by
reducing negative control of the PMN (Diolaiti et al., 2015; Nils-
son et al., 2004; Yang and Hurlin, 2017). In addition, MYC activity
can also be enhanced by loss of MNT (Hurlin et al., 1997, 1999),
which is focally deleted in 10% of all samples, or by inactivation
of MGA, which occurs by focal deletions and by truncating mu-
tations (with 9% and 4% frequency, respectively, Figures 1 and
S2). Since mutual exclusivity between MYC amplification with
deletions or inactivation of other members of the PMN was not
observed, the oncogenic activity of MYC is most likely activated
by a combination of alterations in different PMN members. In
80% of the samples with MYC amplification, MYC is altered in
conjunction with other PMN members. This further highlights
the possibility that activation or loss of any of the negative regu-
lators may balance MYC activity in complex patterns, potentially
as a result of stochastic events (Carroll et al., 2015; Link et al.,
2012). Besides MYC, sole alterations in any of the remaining
PMN members are rarely observed (Figure S4B). However, a
clear quantification of the PMN balance is currently not possible
and future studies are needed to provide evidences on the roles
of the different alterations in the PMN for cancer development.enrichment. Dots below tumor type denote high MYC amplification, while plus sig
corresponding to the canonical MYC signature, orange lines correspond to the no
found in MYCN only. Tables contain main gene sets found in each cluster categ
metabolic gene set.
294 Cell Systems 6, 282–300, March 28, 2018Low-Level Copy-Number Changes Are a Feature of MYC
in Solid Tumors
Previous observations in hematopoietic cell lines and in neu-
roblastoma reported copy-number changes on the order of
10–100 for MYC or MYCN; however, the present analysis
and work from others indicate that, while the frequency of
MYC amplification across solid tumors is highly significant
(TCGA paper in press), the fold copy-number changes are
small (mainly between 0.5 and 2.5). For this reason, copy-
number data were corrected for ploidy enabling a low
threshold to identify single-copy gains of MYC and PMN
members. Even using these inclusive criteria to call samples
with copy-number alterations, we potentially underestimate
the extent of their involvement, as shown in the violin
plots representing copy-number distribution (Figure S1B). In
consideration of the potential heterogeneity and infiltration of
the tumor specimens by non-cancer stromal components,
further analysis will be required to verify copy-number fre-
quencies with lower threshold settings.
Analyzing both amplitude and size of copy-number alterations
ofMYC amplifications unveils three distinct groups. We see sta-
tistically significant differences in MYC amplification size be-
tween tumor types (Figure 2F), but overall each tumor type has
samples fitting into each of the three groups characterized by
either low- and intermediate-amplitude amplifications affecting
a wide range of the chromosome arm, and high amplitude ampli-
fications affecting only a small subset of the chromosome arm.
For deletions, we rarely see loss ofmore than one copy, suggest-
ing that most of the PMNmight be haploinsufficient. This pattern
has been observed in classical tumor suppressors as described
for TP53 andP27KIP1 (Fero et al., 1998; Payne and Kemp, 2005),
and is shown in this dataset and a recent publication (Vidotto
et al., 2018) for PTEN, which exhibits a group with shallow dele-
tions (one copy loss) and a wide range of the chromosome
affected.
Mutually Exclusive Oncogenic Drivers and MYC
Alterations
The frequent copy-number changes ofMYC across many tumor
types and the large body of experimental evidence defines MYC
as a clear oncogenic driver. We used a genome-wide mutual ex-
clusivity analysis withMYC to find genes that are less likely to co-
occur with MYC. Pan-cancer mutual-exclusivity analysis re-
sulted in a higher count of statistically significant results when
compared with tumor-type-specific analysis. This was expected
due to smaller sample sizes in individual tumor types resulting in
loss of statistical power. Strikingly, the top mutually exclusive
genes (PTEN,BRAF, PIK3CA, andAPC) are all known oncogenic
drivers linked to cell signaling (Figures 3 and 4; Table S10). This
observation could be linked to unique and a possibly stochastic
accumulation of genetic alterations in a given cancer, which may
be sufficient to drive tumor formation and therefore appear
mutually exclusive. PTEN, for example, is most frequently
mutated in UCEC, where MYC is also altered at high frequencyns denote high mRNA expression. Blue lines on the heatmaps mark gene sets
n-canonical MYC signature, and yellow lines correspond to neuronal function,
ory. One asterisk marks a WNT signaling gene set, and two asterisks mark a
Figure 7. Heatmap of Correlation (Spearman Rho Value) between miRNA and MYC Expression across the 33 Cancer Studies
OnlymiRNAs that showed an absolute correlation value equal or greater than 0.35 in at least three studies were included (the complete list is provided in Table S9).
Red indicates positive correlation, blue negative correlation.(21%; Figure 4B; Table S10), suggesting that either pathway can
be a driver of the same cancer type. Alternatively, mutual exclu-
sivity between MYC and other recurrently altered genes may be
a reflection that mutations in these oncogenes and tumor sup-
pressors may not increase their fitness and potentially exhibit
synthetic lethality.
Pan-cancer Canonical and Non-canonical MYC-Specific
Gene Set Enrichment
Alteration of MYC expression leads to broad transcriptional
changes through both direct and indirect effects, as observed
in many experimental systems (as reviewed in Kress et al.,
2015). Here, in order to gain an overview at the pan-cancer level
of pathways correlating with MYC expression, we investigated
both positively and negatively correlated genes. Gene set
enrichment analysis was significant only among positively corre-
lated genes, which revealed conserved pathways across 30 of
the 33 tumor types. These pathways comprised DNA replicationand repair processes, including genes such as DNA helicases,
exonucleases, polymerases, and telomerase. Chromatin binding
and remodeling processes were prominent, including acetyla-
tion andmethylation, aswell asmultiple components of the basic
transcription machinery. Altogether, we referred to these gene
sets as canonical pathways, as previously observed in experi-
mental systems upon manipulation of MYC levels (Dominguez-
Sola et al., 2007; Gomez-Roman et al., 2006; Grandori et al.,
2003, 2005; Grewal et al., 2005; Hnisz et al., 2013; Johnston
et al., 1999; Moser et al., 2012; Robinson et al., 2009; for a review
see Ruggero, 2009). Finally, since transcriptional and chromatin
remodeling processes are at the core of MYC and PMN function,
the enrichment in these pathways reflects biological function of
the MYC network, consistent with the strongest correlation in
group I cancers harboring frequent MYC alterations and with
high expression (Figure 6A). Interestingly, MYC-synthetic lethal
genes are enriched for similar pathways to the canonical MYC
signature (Cermelli et al., 2014).Cell Systems 6, 282–300, March 28, 2018 295
The three cancer outliers were THCA, PCPG, and TGCT,
which also have the lowest level of MYC copy-number and
expression changes. THCA, for instances, has a high frequency
of BRAF mutation (Cancer Genome Atlas Research Network,
2014b), which is mutually exclusive to MYC based on our anal-
ysis. This is another indication, that these tumor types are largely
not driven by genetic alterations of MYC.
In addition, a previously unrecognized non-canonical signa-
ture emerged, detectable in groups II and III, comprised of 11 tu-
mor types (Figure 6A), indicating an association ofMYC expres-
sion with extracellular signaling, the immune system (growth
factors and cytokines), and extracellular matrix (Figure 6A). It is
conceivable that upregulation of MYC in these cancers might
occur in response to alterations of signaling pathways, as docu-
mented for WNT signaling in COAD. It is currently unclear how
MYC expression could influence the immune response in a sub-
set of cancers, including KIRP and KICH, UCS, BLCA, and
CHOL. How MYC may influence the tumor immune microenvi-
ronment is of great interest, given the recent study showing
that MYC is able to control PD-L1 and CD47 expression (Casey
et al., 2016). Prominent signaling pathways and immune
response were also observed in group III, with infrequent MYC
copy-number changes (THCA, PCPG, and TGCT). Finally, each
cancer type had a unique ranking of top associated pathways,
indicating potential cancer-type-specific features (Table S7 for
Molecular Processes and Table S8 for Biological Processes).
Future in-depth analysis of these cancer-type-specific pathways
has the potential to give insights about the biology and potential
novel therapeutic vulnerabilities of these tumor types.
Pan-cancerMYCNAlterations and Associated Pathways
To date, MYCN has been largely considered a driver of selected
pediatric cancers, such as neuroblastoma, where 25% of cases
exhibit high levels ofMYCN copy-number gains with clear prog-
nostic significance (Nakagawara et al., 1987). The current anal-
ysis reveals that MYCN alterations, albeit less frequent than
MYC, are widespread across several cancer types (Figure 2B),
pointing to MYCN as a prominent oncogene in adult cancers.
Indeed, similarly to neuroblastoma,MYCN amplification reaches
20% in TCGA cancer samples such as OV, UCS, and LUSC.
Detection of anMYCN-associated gene expression signature al-
lowed for clustering of the 33 cancer types into three groups, ac-
cording to MYCN-specific enriched gene sets. Pathways unique
to MYCN involved neuronal function and development spanning
the majority of cancer types. These MYCN-specific hallmarks
may enable derivation of biomarkers to identify MYCN-driven
cancers that are caused by alterations other than copy-number
changes (Figure 6B). Interestingly, among the gene expression
signatures shared with MYC were aspects of both the canonical
and non-canonical signatures (Figure 6B). Thus, at the pan-can-
cer level, MYC and MYCN appear distinct with respect to tumor
types (with the exception of OV, where both are implicated at
high frequency) and with respect to differences in associated
pathways, which could provide surrogate biomarkers specific
for MYC or MYCN. These results support and broaden, at a
pan-cancer level, previous studies demonstrating a distinction
between MYC and MYCN overexpression on determining spe-
cific cell lineages in geneticmodels ofmedulloblastoma (Roussel
and Robinson, 2013; Vo et al., 2016).296 Cell Systems 6, 282–300, March 28, 2018Conclusions
The data and analyses presented herein are the first compre-
hensive assessment of MYC alterations across diverse tumor
types. Over the years, a large body of evidence for the impor-
tance of MYC in tumorigenesis has been developed and amulti-
tude of biological models created to uncover the complex
mechanisms of MYC function. This study, by integrating this in-
formation with the comprehensive TCGA dataset, provides a
resource for further understanding MYC-driven cancers, spur-
ring new research areas and the basis for novel biomarkers
and therapeutic approaches.STAR+METHODS
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Deposited Data
EB++AdjustPANCAN_IlluminaHiSeq_
RNASeqV2.geneExp.tsv
The Cancer Genome Atlas Research
Network, unpublished data
https://gdc.cancer.gov/about-data/
publications/pancanatlas
TCGA-RPPA-pancan-clean-v2.txt The Cancer Genome Atlas Research
Network, unpublished data
https://gdc.cancer.gov/about-data/
publications/pancanatlas
GISTIC.focal_data_by_genes.conf_95.tsv The Cancer Genome Atlas Research
Network, unpublished data
https://gdc.cancer.gov/about-data/
publications/pancanatlas
pancanMiRs_EBadjOnProtocolPlatformWithout
RepsWithUnCorrectMiRs_08_04_16.csv
The Cancer Genome Atlas Research
Network, unpublished data
https://gdc.cancer.gov/about-data/
publications/pancanatlas
pancan.merged.v0.2.5.filtered.maf.gz The Cancer Genome Atlas Research
Network, unpublished data
https://gdc.cancer.gov/about-data/
publications/pancanatlas
Software and Algorithms
GSEA The Broad Institute https://software.broadinstitute.org/gsea/
index.jsp
DISCOVER The Netherlands Cancer Institute http://ccb.nki.nl/software/discover/
R The R Foundation https://www.r-project.org/Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact Carla
Grandori (carlagrandori@curefirst.org)
METHODS DETAILS
We analyzed TCGA pan-cancer Atlas cohort defined by the whitelist commonly agreed upon by TCGA AWGs for all analyses. The
cohort consisted of 9,125 samples of 33 different histopathologic cancer types representing most major classes of human adult
cancer.
Gene Expression
Gene expression data were available for 20502 genes and 9118 samples across 33 tumor types. (File: EB++AdjustPANCAN_
IlluminaHiSeq_RNASeqV2.geneExp.tsv)
Protein Expression by RPPA: TCGA-RPPA-pancan-clean-v2.txt
Copy Number Variation
The PanCanAtlas Aneuploidy group (Taylor et al. submitted) produced tumor cancer cell ploidy, heterogeneity, and allelic copy num-
ber estimates by running ABSOLUTE (Carter et al., 2012) on segmented Affymetrix SNP6.0 array copy-number data. To evaluate
gene amplification and deletions, the allelic copy number estimates were normalized using thresholded cancer cell ploidy to obtain
new copy ratio estimates adjusted for tumor purity and ploidy. The purity and ploidy valueswere also used to perform ISAR correction
(Zack et al., 2013) on segmented marker-generated copy ratios, which were then used with GISTIC2.0 (Mermel et al., 2011) to
compute relative linear copy number values representing both broad arm-level events and focal events (less than 50% of the chro-
mosome arm), providing metrics to assess the focality of the somatic copy number aberrations.
Overall, we had focal copy number data for 8884 tumor samples, and broad range copy number data for 8785 tumor samples
across 33 tumor types and 24203 genes. (Files: GISTIC.focal_data_by_genes.conf_95.tsv, ABSOLUTE.relative_gene_scores)
miRNA Expression
We analysed miRNA expression data for 662 miRNAs and 10824 samples across 33 tumor types. ( File: pancanMiRs_
EBadjOnProtocolPlatformWithoutRepsWithUnCorrectMiRs_08_04_16.csv)
Somatic Mutations
Only protein coding mutations were retained for downstream analyses (Variant_Classification one of Frame_Shift_Del,Frame_Shift_
Ins,In_Frame_Del,In_Frame_Ins,Missense_Mutation, Nonsense_Mutation, Nonstop_Mutation, Splice_Site, and Translation_Start_
Site). Further mutations calls were required to be made by two or more mutations callers (NCALLERS>1). Overall, mutation calls
were available for 19684 genes for 10133 tumor samples. (File: MC3 Mutation Annotation File pancan.merged.v0.2.5.filtered.maf.gz)Cell Systems 6, 282–300.e1–e2, March 28, 2018 e1
GSEA
The Gene Set Enrichment Analysis tool was used to discover gene sets that were enriched in gene lists ranked by correlation with
MYC and MYCN expression individually. The desktop version for this software is available for download at:
http://software.broadinstitute.org/gsea/index.jsp
DISCOVER
The DISCOVERmethod developed byCanisius et. al. was used to evaluatemutual exclusivity betweenMYCand 24202 genes across
8884 tumor samples encompassing 33 tumor-types. The samemethod was also used to evaluate mutual exclusivity with MYCwithin
individual tumor types. The method is documented on Github at:
https://github.com/NKI-CCB/DISCOVER
QUANTIFICATION AND STATISTICAL ANALYSIS
Gene Alterations
Broad and focal copy number variation data was corrected for tumor ploidy and purity (Carter et al., 2012). For broad range copy
number variation, a corrected value >= 1.5 was considered amplification and a corrected value <= 0.5 was considered deletion.
For focal copy number variation, a corrected value > 0 was considered amplification and a corrected value < 0 was considered
deletion.
For mutual exclusivity analysis as well as for correlation analyses between alterations in MYC network genes and expressions of
various pathways, a gene was considered altered if it had a focal copy number loss or gain or if it had a coding mutation as defined
below in the Data and Software Availability section.
Hedges’ g Effect Size
For Figures 3C and 5A, Hedges’ g (Hedges, 1981) effect sizes were computed to quantify differences between pairs of groups
defined by combined alteration state of MYC with PTEN, BRAF, APC, or PIK3CA respectively. An effect size of magnitude jgj<0.2
was considered ‘‘negligible’’, 0.2<=jgj<0.5 was considered ‘‘small’’, 0.5<=jgj<0.8 was considered ‘‘medium’’, and jgj>=0.8 was
considered ‘‘large’’.
Mutual Exclusivity with MYC
For each of the 24202 protein coding genes across the whole genome, mutual exclusivity with respect to MYC was evaluated using
the DISCOVER method (Canisius et al., 2016). This evaluation was done across all 33 tumor types collectively, as well as for each
tumor type individually. A false discovery rate of 1% was used to indicate statistical significance.
MYC-associated Gene Expression Signature and Gene Set Enrichment Analysis
We computed pairwise Spearman correlation coefficients between each individual MYC gene (c-MYC, MYCN and MYCL) expres-
sion and expressions of 20502 genes (whole genome). The ranked gene list based on decreasing order of Spearman coefficients was
used as input to GSEA (Subramanian et al., 2005; Mootha et al., 2003) to evaluate enrichment of gene sets in the Gene Ontology Mo-
lecular Function category (c5.mf.v5.2.symbols.gmt). Both the correlation analysis and the gene set enrichment analysis were done
separately for each of the 33 different tumor types. The output of GSEA consists of a normalized enrichment score for each gene set
for each tumor type. The enrichment score is normalized for size of the gene set (number of genes in the gene set) and for correlation
between the gene sets and the ranked gene lists. Since gene sets inherently have overlaps in terms of the genes they contain, we
used the reduce_overlap function in the R GOplot package (Walter, Sa´nchez-Cabo, and Ricote, 2015) to retain only those gene
sets in the GSEA results that had less than 75% overlap with other gene sets. In other words, if 2 gene sets had more than 75% over-
lap, only one of them was retained in the result set for downstream analyses and visualizations. The heatmaps in Figure 6 show the
top 100 gene sets with highest median normalized enrichment score (NES) across all the 33 tumor types.
DATA AND SOFTWARE AVAILABILITY
The raw data, processed data and clinical data can be found at the legacy archive of the GDC (https://portal.gdc.cancer.gov/legacy-
archive/search/f) and the PancanAtlas publication page (https://gdc.cancer.gov/about-data/publications/pancanatlas). The muta-
tion data can be found here (https://gdc.cancer.gov/about-data/publications/mc3-2017). TCGA data can also be explored through
the Broad Institute FireBrowse portal (http://gdac.broadinstitute.org) and the Memorial Sloan Kettering Cancer Center cBioPortal
(http://www.cbioportal.org). Details for software availability are in the Key Resource Table.
R Code
Analysis scripts are publicly available at https://github.com/CureFirstResearch/MYC.e2 Cell Systems 6, 282–300.e1–e2, March 28, 2018
